Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: This effect persists after repeated citalopram treatment

被引:53
作者
Gundlah, C
Hjorth, S
Auerbach, SB
机构
[1] RUTGERS STATE UNIV,DEPT SCI BIOL,NELSON LABS,PISCATAWAY,NJ 08854
[2] UNIV GOTHENBURG,DEPT PHARMACOL,GOTHENBURG,SWEDEN
关键词
5-HT; 5-hydroxytryptamine (serotonin); 5-HT autoreceptor; antidepressant; SSRI; microdialysis; hippocampus; frontal cortex; citalopram; (-)-penbutolol; WAY100635;
D O I
10.1016/S0028-3908(97)00052-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The effect of repeated administration of the reuptake inhibitor citalopram (10 mg/kg s.c., b.i.d. for 14 days) or saline on extracellular 5-hydroxytryptamine (5-HT) and autoreceptor sensitivity was assessed using microdialysis in the frontal cortex (FCx) and dorsal hippocampus (DH) of unanesthetized rats. Acute citalopram (5 mg/kg s.c.) challenge produced significant increases in DH and FCx 5-HT. The nonselective 5-HT1A/1B receptor antagonist (-)-penbutolol (8 mg/kg s.c.), administered 2 hr after citalopram challenge, significantly enhanced 5-HT in FCx and DH of both the chronic citalopram and saline pretreatment groups. Administration of the selective 5-HT1A receptor antagonist WAY100635 (0.3 mg/kg s.c.) after citalopram challenge significantly enhanced 5-HT in FCx but not DH of both pretreatment groups. This suggests that there may be differences between DH and FCx in regulation of 5-HT release. Nevertheless, these results provide evidence that 5-HT autoreceptors are still active in restraining 5-HT release even after repeated administration of an antidepressant drug. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:475 / 482
页数:8
相关论文
共 42 条
[1]  
ADELL A, 1991, N-S ARCH PHARMACOL, V343, P237
[2]  
ALBERT PR, 1990, J BIOL CHEM, V265, P5825
[3]  
[Anonymous], 2005, CELL MOL NEUROBIOL, DOI DOI 10.1007/s10571-005-3061-z
[4]  
ARBORELIUS L, 1995, N-S ARCH PHARMACOL, V352, P157
[5]   The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram [J].
Arborelius, L ;
Nomikos, GG ;
Hertel, P ;
Salmi, P ;
Grillner, P ;
Hook, BB ;
Hacksell, U ;
Svensson, TH .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 353 (06) :630-640
[6]   Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists [J].
Artigas, F ;
Romero, L ;
deMontigny, C ;
Blier, P .
TRENDS IN NEUROSCIENCES, 1996, 19 (09) :378-383
[7]  
AUERBACH SB, 1995, N-S ARCH PHARMACOL, V352, P597
[8]   CHRONIC TREATMENT WITH FLUVOXAMINE INCREASES EXTRACELLULAR SEROTONIN IN FRONTAL-CORTEX BUT NOT IN RAPHE NUCLEI [J].
BEL, N ;
ARTIGAS, F .
SYNAPSE, 1993, 15 (03) :243-245
[9]  
BLIER P, 1987, J CLIN PSYCHOPHARM, V7, P245
[10]   CHRONIC TREATMENT WITH FLUVOXAMINE BY OSMOTIC MINIPUMPS FAILS TO INDUCE PERSISTENT FUNCTIONAL-CHANGES IN CENTRAL 5-HT1A AND 5-HT1B RECEPTORS, AS MEASURED BY IN-VIVO MICRODIALYSIS IN DORSAL HIPPOCAMPUS OF CONSCIOUS RATS [J].
BOSKER, FJ ;
VANESSEVELDT, KE ;
KLOMPMAKERS, AA ;
WESTENBERG, HGM .
PSYCHOPHARMACOLOGY, 1995, 117 (03) :358-363